Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance

Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
 
LA JOLLA, Calif.--Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that it has promoted Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance. In this new expanded role Dr. Menzel will oversee the Company's operations and finances, setting strategy to support the advancement of multiple microRNA therapeutic programs towards the clinic.

"The future of Regulus is very bright and we expect to achieve milestones in 2011, including the development of clinical candidates in both our partnered and proprietary programs."
."Over the past two and a half years Garry has provided exemplary leadership at Regulus and has been instrumental in several transformative events for the Company. These include developing our long range strategic plan, transitioning Regulus to an independent C-Corporation, and securing investments and revenues from our pharmaceutical partners sanofi-aventis and GlaxoSmithKline that should provide Regulus with several years of cash going forward," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "The future of Regulus is very bright and we expect to achieve milestones in 2011, including the development of clinical candidates in both our partnered and proprietary programs."

"It is a very exciting time to be part of the leadership team at Regulus and participate in creating a high-value company discovering and developing medicines using a technology platform that targets microRNAs," said Garry E. Menzel, Ph.D., newly promoted Chief Operating Officer and Executive Vice President of Finance of Regulus. "Regulus has quickly established itself as a leader in microRNA therapeutics and offers a rare and exciting opportunity to develop drugs for a brand new target space by leveraging a mature oligonucleotide drug platform."

Before joining Regulus, Dr. Menzel had a long and distinguished career in the financial industry running the global biotechnology practices for Goldman Sachs and Credit Suisse. He joined Goldman Sachs in 1994, where he was a Managing Director and founding member of the Healthcare Group. In 2004, Dr. Menzel joined Credit Suisse as a Managing Director. He served a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements for some of the industry's most significant transactions. Previously, Dr. Menzel was a strategy consultant for Bain & Company, working on a variety of projects in Europe and Asia. Dr. Menzel earned a B.Sc. with Honors in Biochemistry from the Imperial College of Science & Technology in 1985, a Ph.D. in Molecular Biology from the University of Cambridge in 1988, and a M.B.A. from the Stanford Graduate School of Business in 1994. He is an Associate of the Royal College of Science. Dr. Menzel serves as a director on the board of the Institute for Systems Biology and is an executive board member of the Epilepsy Therapy Project, where he chairs the Business Advisory Committee.

About microRNAs

The discovery of microRNA in humans is one of the most exciting scientific breakthroughs in the last decade. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length that do not encode proteins but instead regulate gene expression. Nearly 700 microRNAs have been identified in the human genome, and more than one-third of all human genes are believed to be regulated by microRNAs. As a single microRNA can regulate entire networks of genes, these molecules are considered the master regulators of the genome. microRNAs have been shown to play an integral role in numerous biological processes including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression or function has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function, opens the possibility of a novel class of therapeutics and a unique approach to treating disease by modulating entire biological pathways. To learn more about microRNAs please visit http://www.regulusrx.com/microrna/microrna-explained.php

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in greater than 5,000 human subjects. In addition, Regulus works with a broad network of academic collaborators and leverages oligonucleotide drug discovery and development expertise from its founding companies Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, immuno-inflammatory diseases, fibrosis, oncology, and cardiovascular/metabolic diseases. Regulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus entered into a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of Hepatitis C Viral infection. In June 2010, sanofi-aventis and Regulus entered into the largest-to-date strategic alliance for the development of microRNA therapeutics. This alliance is focused initially on fibrosis. For more information, visit http://www.regulusrx.com

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Any statement describing Regulus' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such party's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause their results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of the management of Regulus, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus' programs are described in additional detail in each of Isis' and Alnylam's annual report on Form 10-K for the year ended December 31, 2009 and their most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from either Isis or Alnylam.

Contacts
Regulus Therapeutics
Zachary Zimmerman, Ph.D., 858-202-6300
[email protected]
or
Russo Partners
Heidi Chokeir, Ph.D. (Media), 619-528-2217
[email protected]


Permalink: http://eon.businesswire.com/news/eon/20110105005407/en

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.